Clinical Trials Logo
  1. Home
  2. Herpes Simplex
  3. NCT00699764

Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease

Herpes Simplex Clinical Trial

Official title:
Safety of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL & Its Efficacy to Prevent Genital Herpes Disease in HSV Positive or Negative Consorts of Subjects With Genital Herpes Disease

Clinical Trial Summary

The purpose of the study is to evaluate the safety of Herpes Simplex candidate vaccine (gD2t) with adjuvant and its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease.

Clinical Trial Description

This study was monitored by a Data Safety Monitoring Board At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00699764
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 3
Start date March 1996
Completion date October 1999
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05468619 - Neonatal Phase 1 Valacyclovir Study Phase 1
Withdrawn NCT02349828 - Antiviral Prophylaxis in a Burn Population Phase 2/Phase 3
Recruiting NCT01176409 - Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2? Phase 3
Completed NCT04664127 - Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
Completed NCT00448227 - Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection Phase 2
Completed NCT00000139 - Herpetic Eye Disease Study (HEDS) II Phase 3
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed NCT02209324 - Open-label Study of ASP2151 in Herpes Simplex Patients Phase 3
Completed NCT00855309 - Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia Phase 3
Completed NCT01602562 - Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients Phase 3
Completed NCT00973466 - Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients N/A
Completed NCT00698893 - Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults Phase 1
Active, not recruiting NCT05298254 - A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes Phase 1/Phase 2
Recruiting NCT03178747 - Tzanck Smear With Methylene Blue Stain for Herpes Phase 3
Completed NCT00164424 - Episodic Acyclovir Therapy for Genital Ulcers Phase 2/Phase 3
Completed NCT00161434 - A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons Phase 4
Terminated NCT04762511 - A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years Phase 1
Recruiting NCT04065971 - Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections. Phase 4
Active, not recruiting NCT00005663 - A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients Phase 3
Recruiting NCT00006132 - Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System Phase 3